Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + tuvonralimab with nab-paclitaxel and carboplatin for treatment-naive advanced thymic carcinoma
ChiCTR2500102923Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel and carboplatin in thymic carcinoma (TC), sponsored by Shandong First Medical University. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxelcarboplatin
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2500102923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102923.